CBA
BTAI icon

Coastal Bridge Advisors’s BioXcel Therapeutics BTAI Stock Holding History

Coastal Bridge Advisors’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,563
Closed -$559K – 154
2020
Q1 		$559K Buy
+1,563
New +$562K 0.21% 62

Other funds holding BTAI

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Coastal Bridge Advisors's BTAI Position: Q2 2020 in Review

Coastal Bridge Advisors sold out of BioXcel Therapeutics (BTAI) in Q2 2020, closing a stake of 1,563 shares — an estimated $559K sold.

Coastal Bridge Advisors first reported a position in BTAI in Q1 2020 and held it in 1 quarter. The position peaked at $559K in Q1 2020. 104 funds tracked by Wall St. Rank hold BTAI as of Q2 2020.

  • Coastal Bridge Advisors reported no remaining BioXcel Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Coastal Bridge Advisors sold 1,563 BioXcel Therapeutics shares in Q2 2020, an estimated $559K.
  • Coastal Bridge Advisors first reported a position in BioXcel Therapeutics in Q1 2020 and held it in 1 quarter.
  • Coastal Bridge Advisors's BioXcel Therapeutics position peaked at $559K in Q1 2020.
  • 104 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2020.

Based on Coastal Bridge Advisors's 13F filing for Q2 2020, filed 11 Aug 2020.